argenx SE American Depositary Receipt (ARGXN)
BMV
Closed
Aug 21, 2026
Day's Range
14,892.2952 wk Range
13,000.67Overview - ARGXN - argenx SE American Depositary Receipt
Key Statistics
Valuation
Enterprise Value
393.32T
P/E (Trailing)
‪33.44‬
Price / Sales (TTM)
‪175.27‬
Price / Book
‪163.13‬
EV / EBITDA
‪14,432.48‬
Profitability
Gross Margin
‪90.42%‬
Profit Margin
‪32.26%‬
Operating Margin
‪31.99%‬
Return on Assets
‪11.63%‬
Return on Equity
‪23.63%‬
Ownership
Shares Outstanding
62.53M
Float
1.56B
Held by Insiders
‪0.00%‬
Held by Institutions
‪46.20%‬
Price stats
Beta
‪-0.04‬
50-Day Avg
‪15,117.25‬
200-Day Avg
‪14,467.77‬
Dividends
Payout Ratio
‪0.00%‬
Market Cap - ARGXN - argenx SE American Depositary Receipt
Peers - ARGXN - argenx SE American Depositary Receipt
Peer Comparison
Compared with companies in Biotechnology listed on BMV.
- ARGXNBMVargenx SE American Depositary Receipt931.67BMarket Cap+4.58%52-week change33.33P/E (Trailing)‪32.26%‬Profit Margin
- ALNYBMVAlnylam Pharmaceuticals Inc742.50BMarket Cap-54.26%52-week change57.14P/E (Trailing)‪16.12%‬Profit Margin
- BNTXNBMVBioNTech SE492.36BMarket Cap+4.53%52-week change1.65P/E (Trailing)‪-63.63%‬Profit Margin
- BMRNBMVBioMarin Pharmaceutical Inc.218.20BMarket Cap+4.43%52-week change192.34P/E (Trailing)‪2.14%‬Profit Margin
- ACADBMVAcadia Pharmaceuticals Inc.77.69BMarket Cap-12.18%52-week change13.46P/E (Trailing)‪33.41%‬Profit Margin
- AGIOBMVAgios Pharmaceuticals Inc.72.95BMarket Cap+0.00%52-week change5.17P/E (Trailing)‪88.25%‬Profit Margin
- ARWRBMVArrowhead Pharmaceuticals Inc.64.20BMarket Cap+0.00%52-week change-45455.00P/E (Trailing)‪-47.79%‬Profit Margin
Profile Summary - ARGXN - argenx SE American Depositary Receipt
About
argenx SE is a global, commercial-stage biopharmaceutical company headquartered in Amsterdam, Netherlands, specializing in antibody-based therapies for severe autoimmune diseases. The company developed and commercializes VYVGART (efgartigimod), the first approved neonatal Fc receptor (FcRn) blocker, which is now…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
